In the evolving landscape of global pharmaceuticals, US trade policies—including 100% tariffs on branded and patented drugs effective October 1, 2025—have catalysed significant shifts. Indian companies are proactively establishing US footholds through acquisitions and investments, while Chinese firms grapple with retaliatory measures and supply chain pivots. Meanwhile, initiatives like Civica Rx are bolstering US domestic production, and the EU is advancing diversification strategies to mitigate vulnerabilities. This article delves into these dynamics, incorporating data up to September 29, 2025, as manufacturing shifts to the U.S. Among the largest producers, Indian and Chinese players dominate, but US policies are driving an increase in capacity, adding 15-20% to output.
Indian Generic Drug Industry’s Pivot To The US
India’s generics sector, supplying 47% of US prescriptions and 20% of global volumes, has intensified US integrations in 2025. Key players like Sun Pharma and Aurobindo are leveraging tie-ups and OFDI to hedge against tariffs, contributing to US capacity growth.
Notable activities:
(a) Acquisitions And Mergers: Aurobindo acquired Lannett for $250 million in July, targeting oncology generics. Syngene (Biocon) purchased Emergent BioSolutions’ facility for $36.5 million in June.
(b) Investments And Tie-Ups: Sun Pharma committed $1-2 billion in capex; Dr. Reddy’s and Cipla formed oncology partnerships.
(c) Manufacturing Hubs: Lupin and Torrent expanded units for complex generics.
(d) OFDI: $500-700 million in partial FY 2025-26.
| Company | Activity Type | Details | Value (USD Million) | Date |
|---|---|---|---|---|
| Aurobindo Pharma | Acquisition | Lannett (respiratory/oncology) | 250 | July 2025 |
| Syngene (Biocon) | Acquisition | Emergent facility (biologics) | 36.5 | June 2025 |
| Sun Pharma | Expansion | Capex for hubs/tie-ups | 1,000-2,000 | 2025 |
| Dr. Reddy’s | Tie-Up | Oncology/respiratory alliances | 200-300 (est.) | Q2-Q3 2025 |
| Lupin | Hub Setup | Repackaging expansion | 150-200 | Sep 2025 |
| Cipla | Tie-Up | Third-party manufacturing | 100-150 | Aug 2025 |
Resilience Of India’s Assembling Industry
India’s “kit-and-assemble” model, analysed in economy myths, features 70-85% Chinese imports ($113-127 billion in 2024) and 15-23% DVA. Relocation to the US would minimally impact GDP (13-17% from manufacturing), with low profits and replaceable taxes.
Tariff Impacts On Branded Drugs
The 100% tariff exempts US plant builders, potentially raising prices 20-50% for 10% of US prescriptions. India’s branded share in US imports is 1-2%, generics-dominant ($20 billion).
| FY | Total Exports to US (USD Bn) | Branded Share (%) | Notes |
|---|---|---|---|
| 2014-15 | 5.2-6.1 | 0.5-0.8 | Generics focus. |
| 2015-16 | 6.3-7.4 | 0.5-0.9 | – |
| 2016-17 | 7.1-8.2 | 0.8-1.1 | Specialty up. |
| 2017-18 | 8.0-9.3 | 1.0-1.4 | – |
| 2018-19 | 9.2-10.5 | 1.0-1.5 | – |
| 2019-20 | 10.1-11.4 | 1.2-1.7 | COVID generics. |
| 2020-21 | 12.3-13.6 | 1.2-1.8 | – |
| 2021-22 | 14.2-15.7 | 1.5-2.0 | FDI peak. |
| 2022-23 | 16.1-17.5 | 1.5-2.1 | – |
| 2023-24 | 18.0-19.4 | 1.8-2.2 | – |
| 2024-25 | 19.2-20.6 | 1.8-2.3 | Generics 31-37%. |
| 2025-26 (Apr-Sep) | 10.5-11.8 | 2.0-2.5 | Tariff shift to generics. |
Potential Tariff Effects On Indian Generics In 2026
Without US hubs by end-2025, 50-100% tariffs could cut $20 billion exports by 20-40%, causing shortages.
Global Generic Makers In The US: Indian Presence
Teva and Sandoz expanded; five Indians (Aurobindo, etc.) represent 50% of new entries.
Indian Pharma OFDI To The US
| FY | Pharma OFDI (USD Mn) | Total OFDI (USD Bn) |
|---|---|---|
| 2023-24 | 300-400 | 3-4 |
| 2024-25 | 500-600 | 4.4 |
| 2025-26 (Apr-Sep) | 300-400 | 2-3 (est.) |
Transition Periods And Capacity Shifts
Generics exempt; branded suspension during builds (1-2 years). Indian shifts: 1-2% capacity ($2-3 billion) in 2023-24, etc.
| FY | Capacity Shift (%) | Capital (USD Bn) |
|---|---|---|
| 2023-24 | 1-2 | 2-3 |
| 2024-25 | 2-3 | 3-4 |
| 2025-26 (Apr-Sep) | 1-2 | 1-2 |
Civica Rx Initiatives: Bolstering US Generic Production
Civica Rx, a nonprofit founded in 2018, has ramped up in 2025 to combat shortages and costs, partnering with global players including Indians.
Key initiatives:
(a) Insulin Expansion: $200 million Petersburg plant for three insulins, $3 million state aid; March collaboration with Biocon Biologics for Insulin Aspart supply.
(b) New Launches: Fourth 2025 launch: low-cost MS treatment via CivicaScript; more by fall.
(c) Facility Growth: Chesterfield lab construction starts summer; hospital memberships expanded.
(d) Partnerships: With BCBS for affordable generics; new meds from own plants.
These efforts reduce US reliance on imports, aligning with reshoring.
EU Pharma Diversification Strategies
The EU’s Critical Medicines Act (CMA), proposed March 11, 2025, addresses shortages by boosting EU manufacturing, diversifying supply chains, and reducing third-country dependence (e.g., China/India). It incentivises resilience via strategic partnerships, collaborative procurement, and global trade. Amid 2024 disruptions, 2025 strategies emphasise domestic strengthening and diversification. This could absorb redirected Chinese exports, enhancing EU access.
Chinese Pharma’s Response: Challenges, Retaliation, And Pivots
Chinese pharma, supplying 20-30% of US generics/APIs, faces acute pressures from 20-245% tariffs effective 2025, risking export chaos and thin margins. Responses include:
(a) Retaliation: 125% tariffs on US pharma exports, escalating tensions; services imports surged 10-fold to $55 billion by 2024.
(b) Supply Chain Adaptations: Investments in compliance, diversification; some relocate production to low-tariff nations or pivot markets.
(c) Export Redirection: Redirecting to EU amid US barriers (up to 245%), potentially flooding markets and aiding EU diversification.
(d) Impacts and Shifts: 10-20% export declines predicted; limited US investments due to geopolitics, but contracts lost to alternatives (e.g., $518M US deal bypassed Chinese firms). Overall, reshoring favors non-Chinese suppliers.
Conclusion
As US tariffs reshape the pharmaceutical sector, India’s strategic US integrations—through acquisitions, investments, and manufacturing hubs—position it for long-term resilience, potentially safeguarding $20 billion in annual exports and maintaining a 47% share of US generics. In contrast, China’s responses, marked by retaliation and market pivots, highlight vulnerabilities that could lead to 10-20% export declines, underscoring the need for diversified strategies. Initiatives like Civica Rx are pivotal in advancing US self-sufficiency, with expansions in insulin and facility growth reducing import reliance and addressing shortages in critical areas like oncology and chronic care. The EU’s diversification under the Critical Medicines Act offers a blueprint for global resilience, emphasising collaborative procurement and reduced dependence on single suppliers, which could absorb redirected flows from China and India.
For stakeholders, actionable steps include: Indian firms should accelerate OFDI and partnerships (aiming for $1-2 billion in additional US capex by mid-2026) to qualify for tariff exemptions; Chinese companies must prioritise EU and emerging market expansions while investing in compliance to mitigate up to 245% tariff impacts; US policymakers could extend transition periods for generics to prevent shortages, targeting a 20-30% domestic capacity boost; and EU entities should forge alliances with Indian generics producers for stable supplies. Overall, these shifts promise a more balanced global supply chain, but proactive monitoring of tariff evolutions and geopolitical tensions is essential to avoid disruptions—stakeholders should track OFDI trends and policy updates quarterly for informed decision-making.